NEWS

Home > News

Title Date
1 CHO Pharma signs MoU with MetaTech, the first collaboration between regenerative medicine and anti-glycan Antibody   2020-05-29
2 CHO Pharma receives the 16th National Innovation Award - Pharmaceutical Category   2019-12-06
3 Comprehensive Patent Portfolio   2020-03-31
4 CHO Pharma Inc received a critical US patent on glycochemistry   2018-10-04
5 CHO Pharma Inc is listed as company on the emerging stock market and aims to be the TSMC in the biotechnology industry   2017-09-28
6 CHO Pharma Inc Aims to be TSMC in Biotechnology Industry   2017-09-28
7 News Release September 26, 2017：The Cho Pharma Inc will be listed as company on the emerging stock market on September 27.   2017-09-26
8 News Release ：The new glycoengineered homogenous anticancer antibody drug of CHO Pharma was approved in the US for Phase I clinical trial.   2017-08-09
9 CHO Pharma is invited by BioTaiwan to present company prospect at “2017 BioBusiness Asia Conference, BBA.”   2017-07-03
10 CHO Pharma’s new drug enters into clinical trial in the US.   2017-03-08
11 Breakthrough in Homogeneous Antibody Development and a New Generation of Glycoarray Technology   2017-01-05
12 Glycan Technology - A New Chapter for Making Antibodies   2017-01-05
13 Academia Sinica Invest Technology Shares in CHO Pharma Inc.   2017-01-05
14 CHO Pharma to present at Boston Taiwanese Biotechnology Symposium   2014-08-21